Skip To Main Content
This platform is for Australian healthcare professionals only
Campus
Campus

ADVENT ASPIRE

ASPIRE is a programme developed for respiratory nurses by respiratory nurses

ASPIRE is developed in collaboration with an expert steering committee and aims to share best practice and experiences, providing practical insights to manage patients with respiratory diseases, such as asthma and chronic rhinosinusitis with nasal polyps, driven by type 2 inflammation.

Eddie Weber

Clinical Nurse Coordinator Allergy, Asthma and Clinical Immunology Service, Alfred Health.

John Harrington

Clinical Nurse Consultant for Airway Disease, Hunter New England Area Health.

Adriana Avram

Clinical Nurse Consultant, Monash Health, Melbourne.

View the latest Interactive Clinical Tutorial on-demand

RECORDED ON: 20 NOVEMBER 2023

Sharing best practice and enriching excellence:
Managing asthma in Australia, what should we aspire to?

What is the new normal in the Australian asthma landscape? What are the outcomes we shouldn’t accept? When should we consider a biological treatment, which one do we choose, what is best for our patient and why? What does asthma remission look like? When should we switch biologics?

In the four on-demand videos below, A/Prof John Blakey, Prof. Peter Wark and respiratory nurses Brooke Kyle, John Harrington (Chair), Eddie Weber and Adriana Avram review the Australian asthma landscape and explore what we should ASPIRE to for patients with severe asthma in 2023 and beyond. View now to find out more from our experts.

Current landscape of asthma in Australia: The new normal that we shouldn’t accept

Presenter: CNC John Harrington
Duration: 27min 53sec

Success in asthma therapies: Remission in asthma; definitions, directions and disagreements

Presenter: A/Prof. John Blakey and CNC Brooke Kyle
Duration: 22min 51sec

Which biologic and why? When to switch to another one?

Presenter: Prof. Peter Wark
Duration: 19min 24sec

Q&A with panel discussion

Facilitated by John Harrington with expert speakers and ASPIRE steering committee
Duration: 11min 33sec

Watch the 2020–2022 ADVENT and ASPIRE series developed and endorsed by Australian and international experts

At ADVENTprogram.com you can:

  • Access medical education resources

  • Review the latest science for Type 2 inflammatory diseases
  • Explore your specific interests – select materials by category or topic

Login to ADVENTprogram.com

Access to ADVENTprogram.com is restricted to healthcare professionals. Registration is required to view content.

Dupixent (dupilumab) PBS Information: Authority Required.

Refer to PBS schedule for full authority information. Authority required for patients aged ≥12 years with chronic severe atopic dermatitis and uncontrolled severe asthma. This product is not listed on the PBS for children 6 to 11 years of age with severe atopic dermatitis or moderate to severe asthma, or for patients with uncontrolled chronic rhinosinusitis with nasal polyps.

Please review full product Information before prescribing Dupixent (dupilumab). Full Product Information is available from Sanofi-aventis Australia pty ltd here or by contacting 1800 818 806.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems

MAT-AU-2302117-1.0  |  FEBRUARY 2024